3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
5
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Neoplasms
6
Lung Neoplasms
4
Colorectal Neoplasms
3
Neoplasm Metastasis
2
Melanoma
2
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Ovarian Neoplasms
1
Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
1
Mesothelioma, Malignant
1
Mesothelioma
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Neuroendocrine
1
Breast Neoplasms
1
Interventions
pembrolizumab
34
Cisplatin
12
Nivolumab
10
atezolizumab
9
Docetaxel
9
Carboplatin
9
Paclitaxel
8
Cetuximab
8
Gemcitabine
7
Blood Specimen Collection
7
Radiotherapy
6
Fluorouracil
6
Drug Therapy
6
cemiplimab
5
Pemetrexed
5
Immune Checkpoint Inhibitors
5
fludarabine
4
Standard of Care
4
Cyclophosphamide
4
spartalizumab
3
epacadostat
3
Surveys and Questionnaires
3
Oncolytic Virotherapy
3
Nicotine
3
Magnetic Resonance Spectroscopy
3
Irinotecan
3
Interleukin-2
3
Filgrastim
3
Bupropion
3
Bortezomib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
dostarlimab
×
Thoracic
×
Clear all
NCT05060432
2024-06-21
TIG-006
iTeos Therapeutics
Phase 1/2
Active not recruiting
153 enrolled